<DOC>
	<DOC>NCT00685191</DOC>
	<brief_summary>The study purpose is to investigate plasma HIV-1 RNA dynamics in subjects initiating raltegravir-based salvage therapy and quantify the corresponding changes in levels of cellular HIV-1 DNA.</brief_summary>
	<brief_title>HIV-1 Viral Dynamics in Subjects Initiating Raltegravir Therapy in Spain</brief_title>
	<detailed_description>First- and second-phase decay rates of plasma HIV-1 RNA and changes in the intracellular levels of HIV-1 proviral DNA and LTR circles will be measured in subjects starting salvage antiretroviral therapy including raltegravir in Spain.</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Raltegravir Potassium</mesh_term>
	<criteria>Patients who have limited or no treatment options due to extensive antiretroviral drug resistance or drug intolerance. Subjects initiating raltegravir plus another fully active antiretroviral drug. Pregnancy, or fertile women willing to be pregnant. Active substance abuse or major psychiatric disease.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>Raltegravir</keyword>
	<keyword>HIV</keyword>
	<keyword>dynamics</keyword>
	<keyword>viral load</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>